Donald Banerji - Concepedia

Author

Donald Banerji

Also Known As

Banerji,Donald, D BANERJI, D Banerji, D Donald Banerji, D. Banerji, D.D. Banerji, Donald Banerji, Donald D. Banerji, K Groenewegen

224

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)Imperial College London Novartis (United Kingdom)Tris Pharma (United States)

About

Donald Banerji is an author at Novartis (United States) specializing in medicine, asthma, and pulmonary disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	1.5K
2	Allergy	9	9	675
3	Allergy Medicine	3	3	147
4	Endocrinology	2	2	210
5	Emergency Medicine	1	1	33

Donald Banerji

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman, New England Journal of Medicine	2016	852
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Jadwiga A. Wedzicha, Marc Decramer, Joachim H. Ficker, The Lancet Respiratory Medicine AsthmaAdvanced Lung DiseaseParallel-group StudyPulmonary MedicineMedicine	2013	538
Dual bronchodilation with QVA149<i>versus</i>single bronchodilator therapy: the SHINE study Eric Bateman, Gary T. Ferguson, Neil Barnes, European Respiratory Journal	2013	377
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Claus Vogelmeier, Eric Bateman, John Pallante, The Lancet Respiratory Medicine Twice-daily Salmeterol–fluticasonePulmonary CareAllergyAdvanced Lung DiseasePulmonary Pharmacology	2012	312
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial Kenneth R. Chapman, John R. Hurst, Stefan Frent, American Journal of Respiratory and Critical Care Medicine	2018	256
Efficacy and safety of NVA237 <i>versus</i> placebo and tiotropium in patients with COPD: the GLOW2 study Edward Kerwin, Jacques Hébert, Nicola Gallagher, European Respiratory Journal	2012	208
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Anthony D’Urzo, Gary T. Ferguson, J.A. van Noord, Respiratory Research	2011	177
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial Nicolás Roche, Kenneth R. Chapman, Claus Vogelmeier, American Journal of Respiratory and Critical Care Medicine	2017	164
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD Santanu Sannigrahi, Changzheng Wang, Xiangdong Zhou, International Journal of COPD	2015	160
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study D. A. Mahler, Marc Decramer, Anthony D’Urzo, European Respiratory Journal	2013	159

Page 1